Radiopharm Theranostics Ltd (RADX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RADX currently has 3.83B outstanding shares. with significant dilution risk as 2.87B authorized shares could dilute existing holders by 74.9%. The company has significantly diluted shareholders by 69.93% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Dec 17, 2025 |
F-3 filing: This F-3 filing from 2025-12-17 details an offering of ADSs representing ordinary shares by selling shareholders. |
3.8B | 2.9B |
| Dec 16, 2025 |
F-3 filing: This F-3 filing from Radiopharm Theranostics Limited describes a combination offering of American Depositary Shares representing Ordinary Shares, with a total proposed amount of $50,000,000, and a subsequent prospectus supplement detailing an at-the-market offering of American Depositary Shares with a proposed amount of $22,400,000 through Leerink Partners LLC. |
2.3B | 2.6B |
| Dec 05, 2024 |
F-1 filing: This F-1 filing outlines a private placement where the company issued ordinary shares and warrants, and discusses the potential sale of these securities by selling shareholders through American Depositary Shares (ADSs). |
2.3B | 2.6B |